HNSAS Stock Overview
A biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Hansa Biopharma AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 21.04 |
| 52 Week High | SEK 57.55 |
| 52 Week Low | SEK 21.04 |
| Beta | 1.18 |
| 11 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | -65.42% |
| 33 Year Change | -90.71% |
| 5 Year Change | -91.43% |
| Change since IPO | -86.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| HNSAS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -5.2% | 0.8% |
| 1Y | -65.4% | -20.1% | 6.6% |
Return vs Industry: HNSAS underperformed the UK Biotechs industry which returned -25.9% over the past year.
Return vs Market: HNSAS underperformed the UK Market which returned -3.8% over the past year.
Price Volatility
| HNSAS volatility | |
|---|---|
| HNSAS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.3% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: HNSAS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HNSAS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 168 | Søren Tulstrup | www.hansabiopharma.com |
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments with rare immunological conditions using its proprietary enzyme technology platform. The company’s lead drug candidate is Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy.
Hansa Biopharma AB (publ) Fundamentals Summary
| HNSAS fundamental statistics | |
|---|---|
| Market cap | SEK 1.72b |
| Earnings (TTM) | -SEK 855.93m |
| Revenue (TTM) | SEK 114.45m |
15.0x
P/S Ratio-2.0x
P/E RatioIs HNSAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNSAS income statement (TTM) | |
|---|---|
| Revenue | SEK 114.45m |
| Cost of Revenue | SEK 49.55m |
| Gross Profit | SEK 64.90m |
| Other Expenses | SEK 920.83m |
| Earnings | -SEK 855.93m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Feb 02, 2024
| Earnings per share (EPS) | -16.32 |
| Gross Margin | 56.70% |
| Net Profit Margin | -747.87% |
| Debt/Equity Ratio | -1,457.5% |
How did HNSAS perform over the long term?
See historical performance and comparison